Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21680691 | 1.00 | MAPT (0.40) | MAPTHTTPOLBPKMGAA | |
| SCHEMBL29518936 | 0.78 | BTK (0.45) | GAAKMT2A | |
| SCHEMBL21707307 | 0.78 | BTK (0.45) | GAAKMT2A | |
| SCHEMBL21774787 | 0.77 | MAPT (0.43) | MAPTHTTPOLBGAAHPGD | |
| SCHEMBL21733423 | 0.77 | MAPT (0.50) | MAPTHTTGAAHPGDALDH1A1 | |
| SCHEMBL23573569 | 0.76 | POLB (0.59) | POLBGAAL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL3196032 | 0.76 | POLB (0.59) | POLBGAAL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL3196038 | 0.76 | POLB (0.59) | POLBGAAL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL23573567 | 0.76 | POLB (0.59) | POLBGAAL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL12487514 | 0.73 | HTT (0.40) | MAPTHTTPOLBPKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11053250-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-12 | — | — | US | disclosed |
| US-20200071333-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | MAPT 1906/4885HTT 925/4885POLB 217/4885 |
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | CYP11B2, CYP11B1, DHPS | MAPT 1906/4885HTT 925/4885POLB 217/4885 |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | IRAK4, IRAK3, IRAK2 | MAPT 1995/4885HTT 3729/4885POLB 2429/4885 |
| US-11053250-B2 | Pyrrolo[1,2-b]pyridazine derivatives | CYP11B2, CYP11B1, DHPS | MAPT 1906/4885HTT 925/4885POLB 217/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | MAPT 1693/4885HTT 3929/4885POLB 2413/4885 |
| US-20200071333-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | MAPT 1906/4885HTT 925/4885POLB 217/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | MAPT 1693/4885HTT 3929/4885POLB 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.